Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which ...

This Copenhagen-based biotech is developing a peptide analog of Amylin's Byetta (glucagon-like peptide 1 (GLP-1)/exendin 4) for type 2 diabetes, which has also shown efficacy in promoting weight loss.

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing, with no agreement ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

CagriSema consists of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA). The combination works by decreasing hunger and increasing ...

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...